AUS
NZ
UK
CA
USA
IND
Highlights
- Atmo receives FDA clearance for gas-sensing capsule.
- Diagnostic device targets gastrointestinal motility disorders.
- U.S. commercial launch expected in July 2025.
Atmo Biosciences (ASX:AT1) has achieved a major milestone with the U.S. Food and Drug Administration (FDA) granting 510(k) clearance for its Atmo Gas Capsule System. This regulatory greenlight allows the company to market its innovative ingestible capsule in the United States for diagnosing gut motility disorders, including gastroparesis and slow transit constipation. The clearance marks a significant inflection point for Atmo’s commercial trajectory, with sales set to begin in July 2025.
The FDA’s decision follows a pivotal multi-centre clinical study, involving 209 participants across 12 sites — 11 in the U.S. and one in Australia. Participants ingested both the Atmo capsule and an existing approved device. The results confirmed Atmo’s capsule delivers equivalent diagnostic performance, particularly in measuring gastric emptying and colonic transit times.
Unlike traditional procedures that often require radiation exposure or hospital stays, the Atmo Gas Capsule offers a non-invasive alternative. Patients are able to go about their normal daily routine while the device collects and transmits essential diagnostic data. This simplifies the process for both clinicians and patients and removes the need for procedures like gastric scintigraphy or radio-opaque marker tests.
Gastrointestinal motility disorders affect millions globally and are notoriously difficult to diagnose accurately. Symptoms such as nausea, bloating, abdominal pain, and irregular bowel movements often go unaddressed due to limitations in traditional diagnostic tools. Atmo’s innovation aims to close this gap, offering a user-friendly, clinically robust solution.
Although Atmo Biosciences is not part of the ASX 200 index, which includes some of Australia's largest and most actively traded stocks (ASX 200), its recent FDA clearance positions it as a key player in the growing digital health and medical diagnostics sector. Investors and industry watchers alike are paying attention as the company prepares for a full-scale commercial rollout in one of the world’s most lucrative healthcare markets.
Atmo Biosciences focuses on pioneering digital health technologies that leverage ingestible sensors to analyse gastrointestinal functions. Its flagship product—the Atmo Gas Capsule—is tailored to support healthcare professionals by providing accurate and comprehensive data for gut health assessments, with potential applications extending into clinical trials and broader research domains.
As regulatory validation aligns with global demand for non-invasive diagnostic tools, Atmo Biosciences may find itself on a strong upward trajectory heading into 2026.
